Analysts’ Weekly Ratings Changes for Paratek Pharmaceuticals (PRTK)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for Paratek Pharmaceuticals (NASDAQ: PRTK):

  • 1/15/2020 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.25 price target on the stock. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 1/8/2020 – Paratek Pharmaceuticals is now covered by analysts at WBB Securities. They set a “buy” rating and a $6.00 price target on the stock.
  • 1/3/2020 – Paratek Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/2/2020 – Paratek Pharmaceuticals is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $14.00 price target on the stock.
  • 12/18/2019 – Paratek Pharmaceuticals was given a new $36.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 11/20/2019 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 11/19/2019 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.75 price target on the stock. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “

Shares of NASDAQ:PRTK traded up $0.07 during midday trading on Thursday, hitting $3.80. The company’s stock had a trading volume of 54,307 shares, compared to its average volume of 2,357,549. The business’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.75. The company has a market cap of $122.67 million, a P/E ratio of -1.06 and a beta of 1.82. Paratek Pharmaceuticals Inc has a 12-month low of $2.66 and a 12-month high of $7.39.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.06. The business had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $3.63 million. Paratek Pharmaceuticals had a negative net margin of 505.07% and a negative return on equity of 5,327.73%. Sell-side analysts forecast that Paratek Pharmaceuticals Inc will post -4.16 EPS for the current year.

In other Paratek Pharmaceuticals news, CEO Evan Loh sold 14,514 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $3.10, for a total value of $44,993.40. Following the completion of the sale, the chief executive officer now owns 417,603 shares of the company’s stock, valued at $1,294,569.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 23,656 shares of company stock worth $73,334. 7.70% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of the business. Granahan Investment Management Inc. MA grew its position in Paratek Pharmaceuticals by 6.8% in the third quarter. Granahan Investment Management Inc. MA now owns 177,873 shares of the specialty pharmaceutical company’s stock valued at $768,000 after acquiring an additional 11,361 shares in the last quarter. State Street Corp increased its holdings in shares of Paratek Pharmaceuticals by 4.9% during the third quarter. State Street Corp now owns 673,779 shares of the specialty pharmaceutical company’s stock valued at $2,911,000 after purchasing an additional 31,526 shares during the period. Trellus Management Company LLC increased its holdings in shares of Paratek Pharmaceuticals by 12.1% during the third quarter. Trellus Management Company LLC now owns 185,000 shares of the specialty pharmaceutical company’s stock valued at $799,000 after purchasing an additional 20,000 shares during the period. California Public Employees Retirement System increased its holdings in shares of Paratek Pharmaceuticals by 5.8% during the third quarter. California Public Employees Retirement System now owns 122,000 shares of the specialty pharmaceutical company’s stock valued at $527,000 after purchasing an additional 6,700 shares during the period. Finally, General American Investors Co. Inc. increased its holdings in shares of Paratek Pharmaceuticals by 59.4% during the third quarter. General American Investors Co. Inc. now owns 749,660 shares of the specialty pharmaceutical company’s stock valued at $3,239,000 after purchasing an additional 279,475 shares during the period. 67.64% of the stock is owned by institutional investors.

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Featured Article: Learning About the VIX – Volatility Index

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.